Multiple sclerosis - natalizumab

Summary

Natalizumab is recommended as a possible treatment for people with rapidly evolving severe relapsing-remitting multiple sclerosis.

Healthcare professionals should not stop prescribing natalizumab for people with other types of multiple sclerosis who were already taking it when the guidance was issued. These people should be able to carry on taking natalizumab until they and their doctor decide that it is the right time to stop.

Documents

For healthcare professionals

• TA127 Multiple sclerosis - natalizumab: guidance
• TA127 Multiple sclerosis - natalizumab: guidance (MS Word format)
• TA127 Multiple sclerosis - natalizumab: quick reference guide

For patients, carers and the public

• TA127 Multiple sclerosis - natalizumab: understanding NICE guidance
• TA127 Multiple sclerosis - natalizumab: understanding NICE guidance (MS Word format)
• TA127 Natalizumab fel triniaeth i oedolion sydd â sglerosis ymledol gweithredol iawn sy'n ailwaelu-dychwelyd: deall canllawiau NICE (fformat MS Word)

Background information

• 2007/046 NICE recommends natalizumab for the treatment of multiple sclerosis
• TA127 Multiple sclerosis - natalizumab: distribution list

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• TA127 Multiple sclerosis - natalizumab: costing template
• TA127 Multiple sclerosis - natalizumab: audit criteria